Orforglipron
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 1400
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Orforglipron Dose 1 (Study GZP1) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 2 (Study GZP1) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 3 (Study GZP1) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 4 (Study GZP1) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Placebo (Study GZP1) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 1 (Study GZP2) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 2 (Study GZP2) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 3 (Study GZP2) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Orforglipron Dose 4 (Study GZP2) | Obesity + T2D | n/r | 4 | n/r | n/r |
| Placebo (Study GZP2) | Obesity + T2D | n/r | 4 | n/r | n/r |